Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 271-283 , April 2008

Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma

  • Bernard Têtu, MD (Professor)

      Affiliations

    • Corresponding Author InformationTel.: +1 418 691 5233; Fax: +1 418 691 5226.

References 

  1. Fair WR, Aprikian A, Reuter V. Neoadjuvant hormonal manipulation: a strategy for chemoprevention trials. Journal of Cellular Biochemistry. Supplement. 1992;16H:118–121
  2. Scott WW, Menon M, Walsh PC. Hormonal therapy of prostatic cancer. Cancer. 1980;45:1929–1936
  3. Lukka H, Waldron T, Klotz L, et al. Maximal androgen blockade for the treatment of metastatic prostate cancer-a systematic review. Current Oncology. 2006;13:81–93
  4. Fleshner N, Zlotta AR. Prostate cancer prevention: past, present, and future. Cancer. 2007;110:1889–1899
  5. Meyer F, Bairati I, Bedard C, et al. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer. Urology. 2001;58:71–77
  6. Sarosdy MF, Schellhammer PF, Johnson R, et al. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?. Urology. 2000;55:391–395
  7. D'Amico AV, Renshaw AA, Loffredo B, et al. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer. 2007;110:1723–1728
  8. Vaillancourt L, Têtu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. American Journal of Surgical Pathology. 1996;20:86–93
  9. Armas OA, Aprikian AG, Melamed J, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. American Journal of Surgical Pathology. 1994;18:979–991
  10. Civantos F, Marcial MA, Banks ER, et al. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer. 1995;75:1634–1641
  11. Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer. 1991;68:821–828
  12. Têtu B, Srigley JR, Boivin JC, et al. Effect of combination endocrine therapy (LHRH Agonist and Flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. American Journal of Surgical Pathology. 1991;15:111–120
  13. van der Kwast TH, Têtu B, Fradet Y, et al. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate. 1996;28:227–231
  14. van der Kwast TH, Têtu B, Suburu ER, et al. Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. The Journal of Pathology. 1998;186:406–409
  15. Witjes WPJ, Schulman CC, Debruyne FMJ. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. Urology. 1997;49:65–69
  16. Labrie F, Cusan L, Gomez J, et al. Neoadjuvant hormonal therapy : the Canadian experience. Urology. 1997;49:56–64
  17. Bono AV, Pagano F, Montironi R, et al. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. Urology. 2001;57:117–121
  18. Fair WR, Cookson MS, Stroumbakis N, et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology. 1997;49:46–55
  19. Amling CL, Blute ML, Bergstralh EJ, et al. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Seminars in Urologic Oncology. 1997;15:222–229
  20. van der Kwast TH, Têtu B, Candas B, et al. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology. 1999;53:523–529
  21. Hellström M, Ranefall P, Webster K, et al. Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer. British Journal of Urology. 1997;79:421–426
  22. Gleave ME, Goldenberg SL, Jones EC, et al. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. The Journal of Urology. 1996;155:213–219
  23. Têtu B. Morphologic changes induced by neoadjuvant combination hormone therapy on prostatic tissue and prostate cancer. Endocrine-Related Cancer. 1996;3:165–170
  24. Maldonado-Valadez R, Teber D, Erdogru T, et al. The impact of neoadjuvant hormonal therapy on the outcome of laparoscopic radical prostatectomy: a matched pair analysis. The Journal of Urology. 2006;175:2092–2096
  25. Soloway MS, Sharifi R, Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Journal of Urology. 1995;154:424–428
  26. Bazinet M, Zheng W, Begin LR, et al. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology. 1997;49:721–725
  27. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. The Journal of Urology. 2001;166:500–506
  28. Schulman CC, Debruyne FM, Forster G, et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. European Urology. 2000;38:706–713
  29. Ohori M, Wheeler TM, Kattan MW, et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. The Journal of Urology. 1995;154:1818–1824
  30. Epstein JI, Pizov G, Webster K. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;71:3582–3593
  31. Catalona WJ, Avioli LV. Diagnosis, staging, and surgical treatment of prostatic carcinoma. Archives of Internal Medicine. 1987;147:361–363
  32. Stamey TA, McNeal JE, Freiha FS, et al. Morphometric and clinical studies on 68 consecutive radical prostatectomies. The Journal of Urology. 1988;139:1235–1241
  33. Tran TA, Jennings TA, Ross JS, et al. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy. American Journal of Surgical Pathology. 1998;22:347–354
  34. Smith DM, Murphy WM. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer. 1994;73:1472–1477
  35. Hellstrom M, Haggman M, Brandstedt S, et al. Histopathological changes in androgen-deprived localized prostatic cancer. A study in total prostatectomy specimens. European Urology. 1993;24:461–465
  36. Kaltz-Wittmer C, Klenk U, Glaessgen A, et al. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Laboratory Investigation. 2000;80:1455–1464
  37. Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clinical Cancer Research. 2001;7:2643–2647
  38. Shi Y, Brands FH, Chatterjee S, et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. The Journal of Urology. 2001;166:1514–1519
  39. Montironi R, Mazzucchelli R, Barbisan F, et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Human Pathology. 2006;37:1137–1144
  40. Montironi R, Magi-Galluzzi C, Muzzonigro G, et al. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. Journal of Clinical Pathology. 1994;47:906–913
  41. Montironi R, Magi-Galluzzi C, Fabris G. Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathology Research and Practice. 1995;191:873–880
  42. Eble JN, Sauter G, Epstein JI, et al. Tumours of the urinary system and male genital organs. [Chapter 3, tumours of the prostate] Lyon: WHO; 2004;
  43. Van de Voorde WM, Elgamal AA, van Poppel H, et al. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. Cancer. 1994;74:3164–3175
  44. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. International Journal of Cancer. 1991;48:189–193
  45. Kruithof-Dekker IG, Têtu B, Janssen PJA, et al. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. The Journal of Urology. 1996;156:1194–1197
  46. Labrie F, Cusan L, Gomez J, et al. Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy in localized prostate cancer. Molecular Urology. 1997;1:253–261
  47. Evans AJ, Humphrey PA, Belani J, et al. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. American Journal of Surgical Pathology. 2006;30:684–693
  48. Ferguson F, Zincke H, Ellison E, et al. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology. 1994;44:91–95
  49. van der Kwast TH, Labrie F, Têtu B. Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Human Pathology. 1999;30:1503–1507
  50. Grignon D, Troster M. Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy. Prostate. 1985;7:195–202
  51. Helpap B. Treated prostatic carcinoma. Histological, immunohistochemical and cell kinetic studies. Applied Pathology. 1985;3:230–241
  52. van Poppel H, De Ridder D, Elgamal AA, et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Journal of Urology. 1995;154:429–434
  53. Dhom G, Degro S. Therapy of prostatic cancer and histopathologic follow-up. Prostate. 1982;3:531–542
  54. Dalkin BL, Ahmann FR, Nagle R, et al. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. The Journal of Urology. 1996;155:1357–1360
  55. Goldenberg SL, Klotz LH, Srigley JR, et al. Randomized prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. The Journal of Urology. 1996;156:873–877
  56. Bullock MJ, Srigley JR, Klotz LH, et al. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. American Journal of Surgical Pathology. 2002;26:1400–1413
  57. Gleave M, Qian J, Andreou C, et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer–results from a 4-month pre-radical prostatectomy study. Prostate. 2006;66:1674–1685
  58. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. The New England Journal of Medicine. 2003;349:215–224
  59. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the prostate cancer prevention trial. Journal of National Cancer Institute. 2007;99:1375–1383
  60. Thompson IM, Lucia MS, Redman MW, et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. The Journal of Urology. 2007;178:107–109
  61. Aus G, Abrahamsson PA, Ahlgren G, et al. Hormonal treatment before radical prostatectomy: a 3-year followup. The Journal of Urology. 1998;159:2013–2016

PII: S1521-690X(08)00006-7

doi: 10.1016/j.beem.2008.01.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 271-283 , April 2008

Article Tools

* Image Usage & Resolution